-
Correction to ‘In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank’ Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-27
Boonpor, J, Pell, JP, Ho, FK, Celis-Morales, C, Gray, SR. In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank. Diabetes Obes Metab. 2024; 26(2): 524–531. doi:10.1111/dom.15338 In references 23 and 25, the authors' first names have been used instead of their last names. The correct references 23 and 25
-
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-27 Snežana Milanović, Nina Dedic, Robert Lew, Duane Burton, Kenneth S. Koblan, Michael Camilleri, Seth C. Hopkins
BackgroundMetabolic syndrome (MetS), which can be induced or exacerbated by the current class of antipsychotic drugs, is highly prevalent in patients with schizophrenia and presents significant challenges to lifetime disease management. Supported by initial clinical results, trace amine‐associated receptor 1 (TAAR1) agonists have emerged as potential novel treatments for schizophrenia. Notably, non‐clinical
-
-
Comparison of estimated glomerular filtration rate change with sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists among people with diabetes: A propensity‐score matching study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Yuta Suzuki, Hidehiro Kaneko, Hajime Nagasawa, Akira Okada, Katsuhito Fujiu, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Tomohito Gohda, Yusuke Suzuki, Koichi Node, Hideo Yasunaga, Masaomi Nangaku, Issei Komuro
AimTo compare the risk of developing kidney outcomes with use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) versus use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors among individuals with diabetes.Materials and MethodsIn this retrospective observational study, we analysed 12 338 individuals with diabetes who newly initiated SGLT2 inhibitors or GLP‐1RAs using data from the JMDC claims
-
Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Bertrand Cariou, Jennifer Linge, Ian J. Neeland, Olof Dahlqvist Leinhard, Mikael Petersson, Laura Fernández Landó, Ross Bray, Ángel Rodríguez
AimsTo describe the overall fat distribution patterns independent of body mass index (BMI) in participants with type 2 diabetes (T2D) in the SURPASS‐3 MRI substudy by comparison with sex‐ and BMI‐matched virtual control groups (VCGs) derived from the UK Biobank imaging study at baseline and Week 52.MethodsFor each study participant at baseline and Week 52 (N = 296), a VCG of ≥150 participants with
-
Intra‐pancreatic fat is associated with continuous glucose monitoring metrics Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Yutong Liu, Wandia Kimita, Xiatiguli Shamaitijiang, Loren Skudder‐Hill, Ivana R. Sequeira‐Bisson, Maxim S. Petrov
AimTo investigate the relationship of fat in the pancreas with time spent in different glycaemic ranges.MethodsAbdominal magnetic resonance imaging at 3.0 Tesla was used to quantify fat in the pancreas as both continuous [i.e. intra‐pancreatic fat deposition (IPFD)] and binary (i.e. fatty change of the pancreas vs. normal pancreas) variables. Dexcom G6 devices were used to collect continuous glucose
-
Maladaptive response following glucose overload in GLUT4‐overexpressing H9C2 cardiomyoblasts Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Bernd Stratmann, Britta Eggers, Yvonne Mattern, Tayana Silva de Carvalho, Katrin Marcus‐Alic, Diethelm Tschoepe
BackgroundGlucose overload drives diabetic cardiomyopathy by affecting the tricarboxylic acid pathway. However, it is still unknown how cells could overcome massive chronic glucose influx on cellular and structural level.Methods/MaterialsExpression profiles of hyperglycemic, glucose transporter‐4 (GLUT4) overexpressing H9C2 (KE2) cardiomyoblasts loaded with 30 mM glucose (KE230L) and wild type (WT)
-
The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Yu Zhang, Danning Yang, Qiufeng Jia, Jie Yan, Fengshuang An
AimsTo conduct an updated systematic review and meta‐analysis to evaluate the efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) with regard to cardiac function and structure in people with or without type 2 diabetes mellitus (T2DM).Materials and MethodsWe conducted a systematic search using the PubMed, Embase and ClinicalTrials.gov online databases. The primary outcome of interest was
-
The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through ‘stacking’ of drugs from different classes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-22 David S. H. Bell, Terri Jerkins
Aggressive therapy of diabetic kidney disease (DKD) can not only slow the progression of DKD to renal failure but, if utilized at an early enough stage of DKD, can also stabilize and/or reverse the decline in renal function. The currently recognized standard of therapy for DKD is blockade of the renin‐angiotensin system with angiotensin‐converting enzyme (ACE) inhibitors or angiotensin II receptor
-
During an 18‐month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-22 Mari‐Anne Pulkkinen, Tero J. Varimo, Elina T. Hakonen, Matti T. Hero, Päivi J. Miettinen, Anna‐Kaisa Tuomaala
AimsTo investigate whether the positive effects on glycaemic outcomes of 3‐month automated insulin delivery (AID) achieved in 2‐ to 6‐year‐old children endure over an extended duration and how AID treatment affects time in tight range (TITR), defined as 3.9–7.8 mmol/L.Research Design and MethodsWe analysed 18 months of follow‐up data from a non‐randomized, prospective, single‐arm clinical trial (n
-
Practical strategies to manage obesity in type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-22 Helena W. Rodbard, Katharine Barnard‐Kelly, Andreas F. H. Pfeiffer, Carina Mauersberger, Oliver Schnell, Francesco Giorgino
The rising phenomenon of obesity, a major risk factor for the development and progression of type 2 diabetes, is a complex and multifaceted issue that requires a comprehensive and coordinated approach to be prevented and managed. Although novel pharmacological measures to combat obesity have achieved unprecedented efficacy, a healthy lifestyle remains essential for the long‐term success of any therapeutic
-
Could poor glycaemic control be a predictor of walking speed decline in older adults? Evidence from the English Longitudinal Study of Ageing Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-22 Mariane M. Luiz, Roberta de O. Máximo, Dayane C. de Oliveira, Paula C. Ramírez, Aline F. de Souza, Maicon L. B. Delinocente, Natália Cochar‐Soares, Andrew Steptoe, Cesar de Oliveira, Tiago da S. Alexandre
AimAlthough diabetes is a risk factor for walking speed decline in older adults, it remains unclear how glycaemic control [assessed by glycated haemoglobin (HbA1c)] might affect the long‐term trajectories of walking speed. We investigated whether the glycaemic control status accelerates the walking speed decline and whether this decline differs depending on previous mobility conditions.Materials and
-
The effect of bolus advisors on glycaemic parameters in adults with diabetes on intensive insulin therapy: A systematic review with meta-analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-19 Elisabeth J. den Brok, Cecilie H. Svensson, Maria Panagiotou, Marleen M. J. van Greevenbroek, Peter R. Mertens, Andriani Vazeou, Asimina Mitrakou, Konstantinos Makrilakis, Gregor H. L. M. Franssen, Sander van Kuijk, Stephan Proennecke, Stavroula Mougiakakou, Ulrik Pedersen-Bjergaard, Bastiaan E. de Galan
To conduct a systematic review with meta-analysis to provide a comprehensive synthesis of randomized controlled trials (RCTs) and prospective cohort studies investigating the effects of currently available bolus advisors on glycaemic parameters in adults with diabetes.
-
The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-21 Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal
Despite its considerable and growing burden, there are currently no Food and Drug Administration‐approved treatments for metabolic dysfunction‐associated steatotic liver disease or its progressive form, metabolic dysfunction‐associated steatohepatitis (MASH). Several glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and other agents are in various phases of clinical development for use in MASH;
-
Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-20 Frederick Berro Rivera, Grace Nooriza O. Lumbang, Danielle Rose Magno Gaid, Linnaeus Louisse A. Cruz, John Vincent Magalong, Nathan Ross B. Bantayan, Kyla M. Lara‐Breitinger, Martha Gulati, George Bakris
AimThe cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) extend beyond weight reduction and glycaemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP‐lowering effects of GLP1‐RAs.MethodsA comprehensive database search for placebo‐controlled randomized controlled trials on GLP‐1RA treatment was conducted until
-
The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-20 Sima Fansa, Andres Acosta
Over the past few decades, there has been a global surge in the prevalence of obesity, rendering it a globally recognized epidemic. Contrary to simply being a medical condition, obesity is an intricate disease with a multifactorial aetiology. Understanding the precise cause of obesity remains a challenge; nevertheless, there seems to be a complex interplay among biological, psychosocial and behavioural
-
Dipeptidyl peptidase‐4 inhibitor and sodium‐glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high‐fat diet‐fed mice Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-20 Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Yuka Nogami, Yoshiko Shirakiya, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
AimDipeptidyl peptidase‐4 (DPP‐4) inhibitors suppress the inactivation of incretin hormones and lower blood glucose levels by inhibiting DPP‐4 function. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels in an insulin‐independent manner by inhibiting renal reabsorption of glucose. DPP‐4 and SGLT2 inhibitors each have the potential to improve hepatic steatosis; however, their
-
The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-19 Xiao Wen Luah, Thomas Holst‐Hansen, Christopher Lübker
AimTo provide an updated estimate of the association between body mass index (BMI) and health‐related quality of life (HRQoL) among the general population in England and to identify population subgroups with the highest potential utility gains from obesity interventions.Materials and MethodsThe sample included 12 158 adults with valid HRQoL and BMI data from the 2017 and 2018 Health Survey for England
-
The GPR40 novel agonist SZZ15‐11 improves non‐alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet‐induced obese mice Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-18 Lei Lei, Xuefeng Gao, Jiayu Zhai, Shuainan Liu, Quan Liu, Caina Li, Hui Cao, Cunyu Feng, Leilei Chen, Liran Lei, Xuan Pan, Pingping Li, Zhanzhu Liu, Yi Huan, Zhufang Shen
AimNon‐alcoholic fatty liver is the most common cause of chronic liver disease. GPR40 is a potential therapeutic target for energy metabolic disorders. GPR40 is a potential therapeutic target for energy metabolic disorders. SZZ15‐11 is a newly synthesized GPR40 agonist. In this study, we estimate the potency of SZZ15‐11 in fatty liver treatment.MethodsIn vivo, diet‐induced obese (DIO) mice received
-
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-18 Stefan R. Bornstein, Dick de Zeeuw, Hiddo J. L. Heerspink, Friedrich Schulze, Lisa Cronin, Arne Wenz, Katherine R. Tuttle, Samy Hadjadj, Peter Rossing
AimThis Phase I study evaluated the safety and early efficacy of an aldosterone synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney disease.MethodsDouble‐blind, placebo‐controlled study (NCT03165240) at 40 sites across Europe. Eligible participants [estimated glomerular filtration rate ≥20 and <75 ml/min/1.73 m2; urine albumin/creatinine ratio (UACR) ≥200 and <3500
-
Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-18 Chenyang Shi, Yijiong Tan, Shanshan Hu, Yingyi Qin, Yuanjun Tang, Yufan Wang, Guorong Fan
CONFLICT OF INTEREST STATEMENT The authors declare no potential conflicts of interest.
-
Effects of home-based exergaming on cardio-metabolic and cognitive health in physically inactive individuals Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-13 Andreas Melmer, Anna Lisa Martin-Niedecken, Wanda Wehrli, Patrick Lüchinger, Yanick Riederer, Sam Scott, Jordan Pickles, Stephan Niedecken, David Flagmeier, Stephan Villiger, Roman Jurt, Nicole Kind, Lilian Witthauer, Alexandra Schättin, Christoph Stettler
To examine the effects of a home-based exergame training over 6 weeks on cardio-metabolic and cognitive health, as well as training adherence, in physically inactive individuals.
-
Analyses of potential causal contributors to increased waist/hip ratio‐associated cardiometabolic disease: A combined and sex‐stratified Mendelian randomization study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-16 Habiba Hashemy, Anthony Nguyen, Rana Khafagy, Delnaz Roshandel, Andrew D. Paterson, Satya Dash
BackgroundIncreased waist/hip ratio (WHR) contributes to type 2 diabetes, fatty liver, dyslipidaemia, hypertension and coronary artery disease, with potential sex‐differential effects. Postulated mediators include increased lipid flux, branched‐chain amino acids, glycine and glycoprotein acetyl, but their relative contributions and sex‐specific impact on WHR‐associated cardiometabolic disease (CMD)
-
Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost‐effective in select individuals Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-16 Darren Lau, Glen J. Pearson, Paolo Raggi, Scott Klarenbach
1 BACKGROUND Many adults with diabetes are not on a statin.1 A coronary artery calcium (CAC) scan provides a depiction of coronary artery disease and is predictive of cardiovascular (CV) risk. Showing and discussing CAC scan findings with patients has been shown to increase the use of preventive medications.2, 3 Even in trials where CAC-based intervention reduced the use of statins (e.g., due to enrolment
-
Efficacy of 1-hour postload plasma glucose as a suitable measurement in predicting type 2 diabetes and diabetes-related complications: A post hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-15 Minying Peng, Siyao He, Jinping Wang, Yali An, Xin Qian, Bo Zhang, Lihong Zhang, Bo Chen, Zhiwei Yang, Guangwei Li, Qiuhong Gong
To evaluate whether 1-hour plasma glucose (1hPG) can be a comparable measurement to 2-hour plasma glucose (2hPG) in identifying individuals at high risk of developing diabetes.
-
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-13 Gian Paolo Fadini, Benedetta Maria Bonora, Mariangela Ghiani, Roberto Anichini, Elena Melchionda, Bruno Fattor, Stefano Fazion, Giancarla Meregalli, Andrea Giaccari, Angelo Avogaro, Agostino Consoli
To investigate the real-world utilization and comparative clinical outcomes of injectable and oral semaglutide in individuals with type 2 diabetes (T2D) with the aim of enhancing understanding of the practical implications associated with choosing between these formulations.
-
Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-13 Gabriel P. A. Costa, Vitor R. Y. Moraes, Beatriz R. Assunção, Nora Burns, Sobia Laique, Shreya Sengupta, Akhil Anand, Julio C. Nunes
AimsTo conduct a systematic review and meta‐analysis with the aim of synthesizing existing data on the efficacy and safety of topiramate as an adjunctive treatment for reducing second‐generation antipsychotic (SGA)‐associated weight gain in children aged 4–18 years.MethodsWe conducted a comprehensive search of PubMed, Embase, PsychNet and Web of Science from time of their inception up to 12 February
-
Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-12 Thomas Nyström, Mikael Andersson Franko, Johnny Ludvigsson, Marcus Lind, Martina Persson
1 BACKGROUND Retinopathy is the most prevalent microvascular complication of type 1 diabetes (T1D), often present during adolescence and eventually affecting the vast majority of subjects with T1D.1 Retinopathy is associated with significant risks of cardiovascular morbidity and preterm mortality.2 Important risk factors for retinopathy include hyperglycaemia, dyslipidaemia, hypertension, obesity and
-
The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-12 Wissam Ghusn, Sima Fansa, Diego Anazco, Elif Tama, Lizeth Cifuentes, Khushboo Gala, Alan De La Rosa, Daniel Sacoto, Alejandro Campos, Fauzi Feris, Daniela Hurtado, Andres Acosta
AimsTo compare weight loss outcomes between patients starting semaglutide who had previously been on another anti‐obesity medication (AOM) compared to those who were AOM‐naïve.Materials and MethodsWe performed a retrospective study in patients with overweight or obesity taking semaglutide for weight loss for a duration of 3 to 12 months. Our primary endpoint was assessment of percentage of total body
-
Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (PIONEER REAL Canada) Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-12 Akshay B. Jain, Sonja M. Reichert, Hanan Amadid, Uffe C. Braae, Ryan M. Bradley, James W. Kim, Victoria Soo, Jean‐François Yale
AimPIONEER REAL Canada examined real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes.Materials and MethodsThis was a 34‐ to 44‐week, multicentre, prospective, open‐label, non‐interventional study in adults who were treatment‐naive to injectable glucose‐lowering medication and initiated oral semaglutide in routine clinical practice. The primary
-
The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-12 Rachelle Haber, Fatima Zarzour, Malak Ghezzawi, Natalie Saadeh, Dania S. Bacha, Lama Al Jebbawi, Marlene Chakhtoura, Christos S. Mantzoros
There are conflicting data on the weight‐reducing potential of metformin (MTF) in nondiabetic patients with obesity. The purpose of this systematic review and meta‐analysis was to evaluate the effect of MTF on weight and cardiometabolic parameters in adults with overweight/obesity with or without nonalcoholic fatty liver disease (NAFLD) (CRD42018085512). We included randomized controlled trials (RCTs)
-
Low‐grade inflammation in persons with recently diagnosed type 2 diabetes: The role of abdominal adiposity and putative mediators Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-11 Sidsel L. Domazet, Thomas B. Olesen, Jacob V. Stidsen, Camilla K. Svensson, Jens S. Nielsen, Reimar W. Thomsen, Niels Jessen, Peter Vestergaard, Mette K. Andersen, Torben Hansen, Charlotte Brøns, Verena H. Jensen, Allan A. Vaag, Michael H. Olsen, Kurt Højlund
AimsTo determine the magnitude of the association between abdominal adiposity and low‐grade inflammation in persons with recently diagnosed type 2 diabetes (T2D) and to determine to what extent this association is mediated by low physical activity level, hyperinsulinaemia, hyperglycaemia, dyslipidaemia, hypertension, and comorbidities.Materials and MethodsWe measured waist circumference, clinical characteristics
-
Hydrogel dressings for diabetic foot ulcer: A systematic review and meta‐analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-11 Hongjiao Zhao, You Wu, Yuchen Xie, Yanfei Li, Chen Chen, Chanjuan Li, Fangzheng Yang, Deteng Zhang, Yaqin Wang, Junhua Yuan
AimTo investigate the differences in utility between conventional dressings and hydrogel dressings for the treatment of diabetic foot ulcer (DFU).MethodsThe PubMed, Embase, Cochrane Library, CNKI, VIP and Wanfang databases were systematically searched up to 21 January 2023. Fixed/random‐effect models were used to calculate the odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals
-
Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-08 Marga A. G. Helmink, Steven H. J. Hageman, Björn Eliasson, Naveed Sattar, Frank L. J. Visseren, Jannick A. N. Dorresteijn, Katie Harris, Sanne A. E. Peters, Mark Woodward, Péter Szentkúti, Kurt Højlund, Jan Erik Henriksen, Henrik Toft Sørensen, Erik H. Serné, Thomas T. van Sloten, Reimar W. Thomsen, Jan Westerink
AimsTo develop and externally validate the LIFE‐T1D model for the estimation of lifetime and 10‐year risk of cardiovascular disease (CVD) in individuals with type 1 diabetes.Materials and MethodsA sex‐specific competing risk‐adjusted Cox proportional hazards model was derived in individuals with type 1 diabetes without prior CVD from the Swedish National Diabetes Register (NDR), using age as the time
-
Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-08 Djordje S. Popovic, Dimitrios Patoulias, Paschalis Karakasis, Theocharis Koufakis, Nikolaos Papanas
CONFLICT OF INTEREST STATEMENT None to declare.
-
A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-08 Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh, Kun‐Ho Yoon
AimTo evaluate the long‐term safety and efficacy of enavogliflozin 0.3 mg/day added to metformin in patients with type 2 diabetes mellitus.Materials and MethodsAfter 24 weeks of a randomized, double‐blind treatment period with enavogliflozin 0.3 mg/day (n = 101) or dapagliflozin 10 mg/day (n = 99) added to metformin, all patients received enavogliflozin 0.3 mg/day plus metformin for an additional 28
-
Sex‐specific associations between haemoglobin glycation index and the risk of cardiovascular and all‐cause mortality in individuals with pre‐diabetes and diabetes: A large prospective cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-08 Jingqi Yang, Qing Shangguan, Guobo Xie, Ming Yang, Guotai Sheng
AimThe aim of this study was to investigate the relationship between the haemoglobin glycation index (HGI), and cardiovascular disease (CVD) and all‐cause mortality in adults with pre‐diabetes and diabetes.MethodsThis study included 10 267 adults with pre‐diabetes and diabetes from the National Health and Nutrition Examination Survey (NHANES) 1999‐2018. Sex‐differentiated relationships between HGI
-
Ingesting probiotic yogurt containing Lactiplantibacillus plantarum OLL2712 improves glycaemic control in adults with prediabetes in a randomized, double-blind, placebo-controlled trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-07 Takayuki Toshimitsu, Ayako Gotou, Toshihiro Sashihara, Kenichi Hojo, Satoshi Hachimura, Nobuhiko Shioya, Yoshitaka Iwama, Junichiro Irie, Yoshitatsu Ichihara
The ingestion of Lactiplantibacillus plantarum OLL2712 (OLL2712) cells has been shown to improve glucose metabolism by suppressing chronic inflammation in murine models and clinical studies. This study aimed to clarify the effect of OLL2712 on glycaemic control in healthy adults with prediabetes.
-
Acquired hypothalamic obesity: A clinical overview and update Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-07 Christian L. Roth, Shana E. McCormack
Hypothalamic obesity (HO) is a rare and complex disorder that confers substantial morbidity and excess mortality. HO is a unique subtype of obesity characterized by impairment in the key brain pathways that regulate energy intake and expenditure, autonomic nervous system function, and peripheral hormonal signalling. HO often occurs in the context of hypothalamic syndrome, a constellation of symptoms
-
Performance of new and panel CKD‐EPI equations in European adults with type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-07 Esben Iversen, Katrine McLain Christensen, Anne Byriel Walls, Mie Klessen Eickhoff, Bernt Johan von Scholten, Marie Frimodt‐Møller, Tine Willum Hansen, Frederik Persson, Peter Rossing, Viktor Rotbain Curovic, Morten Baltzer Houlind
1 BACKGROUND Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D) characterized by albuminuria and a progressive decline in the glomerular filtration rate (GFR).1 CKD in the setting of T2D can be the result of diabetic nephropathy, non-diabetic renal disease, or a combination of these factors.2 Regardless of the aetiology, early diagnosis of CKD enables interventions to slow
-
Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-07 Giovanni Antonio Silverii, Christian Marinelli, Edoardo Mannucci, Francesco Rotella
CONFLICT OF INTERESTS STATEMENT GAS has received financial support and speaking fees from Astra Zeneca, Eli Lilly and Novo Nordisk outside the present paper; EM has received speaking fees from Astra Zeneca, Eli Lilly, Merck, Novo Nordisk and Sanofi, research grants from Eli Lilly and Novo Nordisk, outside the present paer; CM and FR have no conflict of interest to declare.
-
The role of real‐time continuous glucose monitoring in diabetes management and how it should link to integrated personalized diabetes management Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-05 Monika Reddy, Nick Oliver
Diabetes is a complex metabolic condition that demands tailored, individualized approaches for effective management. Real‐time continuous glucose monitoring (rtCGM) systems have improved in terms of design, usability and accuracy over the years and play a pivotal role in the delivery of integrated personalized diabetes management (iPDM). iPDM is a comprehensive multidisciplinary approach that combines
-
-
Associations of diabesity with all‐cause and cardiovascular disease mortality: Findings from the Mexico City Prospective Study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-05 Fanny Petermann‐Rocha, Evelia Apolinar, Gabriela Nazar, Felipe Diaz‐Toro, Andrés Celis, Salil Deo, Gerson Ferrari, Gary O'Donovan
AimTo investigate the joint associations of diabetes and obesity with all‐cause and cardiovascular disease (CVD) mortality in the Mexico City Prospective Study.Materials and MethodsIn total, 154 128 participants (67.2% women) were included in this prospective analysis. Diabetes was self‐reported, while body mass index was used to calculate obesity. Using diabetes and obesity classifications, six groups
-
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Jonah A. Hoyt, Emily Cozzi, David A. D'Alessio, Chris C. Thompson, Vanita R. Aroda
Affecting 5%–10% of the world population, type 2 diabetes (T2DM) is firmly established as one of the major health burdens of modern society. People with T2DM require long‐term therapies to reduce blood glucose, an approach that can mitigate the vascular complications. However, fewer than half of those living with T2DM reach their glycaemic targets despite the availability of multiple oral and injectable
-
Pre‐dinner walks may be superior to post‐dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed‐loop insulin delivery systems Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Lauren V. Turner, Michael C. Riddell
1 INTRODUCTION Individuals with type 1 diabetes (T1D) often experience elevated blood glucose levels after a meal, which can lead to long-term complications, including microvascular or macrovascular disease.1, 2 Previous studies have shown that light to moderate intensity activity post-meal can reduce glucose levels in individuals with T1D.3-5 However, these studies were limited to morning post-meal
-
Accelerated onset of diabetes in non‐obese diabetic mice fed a refined high‐fat diet Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Heidi M. Batdorf, Luz de Luna Lawes, Gabrielle A. Cassagne, Molly S. Fontenot, Innocence C. Harvey, Jeremy T. Richardson, David H. Burk, Samuel D. Dupuy, Michael D. Karlstad, J. Michael Salbaum, Jaroslaw Staszkiewicz, Robbie Beyl, Sujoy Ghosh, Susan J. Burke, J. Jason Collier
AimType 1 diabetes results from autoimmune events influenced by environmental variables, including changes in diet. This study investigated how feeding refined versus unrefined (aka ‘chow’) diets affects the onset and progression of hyperglycaemia in non‐obese diabetic (NOD) mice.MethodsFemale NOD mice were fed either unrefined diets or matched refined low‐ and high‐fat diets. The onset of hyperglycaemia
-
Retinal vascular density as a potential biomarker of diabetic cerebral small vessel disease Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Yinqiong Huang, Siyun Wang, Chi Cai, Xinwei Huang, Yan Chen, Xiaohong Wu, Yiping Zhang, Yan Zhang, Xiahong Lin
AimThe retina and brain share similar anatomical and physiological features. Thus, retinal imaging by optical coherence tomography angiography (OCTA) might be a potential tool for the early diagnosis of diabetic cerebral small vessel disease (CSVD). In this study, we aimed to evaluate retinal vascular density (VD) in diabetic CSVD by OCTA imaging and explore the associations between retinal VD and
-
Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Yuliya Tishova, Svetlana Kalinchenko, George Mskhalaya, Geoffrey Hackett, Mark Livingston, Carola König, Richard Strange, Michael Zitzmann, Amar Mann, Amro Maarouf, Sudarshan Ramachandran
AimsTo describe changes in homeostasis model assessment of insulin resistance index (HOMA‐IR) following testosterone therapy in men with hypogonadism and metabolic syndrome (MetS).Materials and MethodsA randomized, placebo‐controlled, double‐blind randomized controlled trial (RCT) comprising 184 men with MetS and hypogonadism (testosterone undecanoate [TU]: 113 men, placebo: 71 men) was conducted.
-
-
A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-01 Soo Lim, Seung‐Hwan Lee, Kyung‐Wan Min, Chang Beom Lee, Sang Yong Kim, Hye Jin Yoo, Nan Hee Kim, Jae Hyeon Kim, Seungjoon Oh, Jong Chul Won, Hyuk Sang Kwon, Mi Kyung Kim, Jung Hwan Park, In‐Kyung Jeong, Sungrae Kim
AimTo investigate the efficacy and safety of pioglitazone compared to placebo when added to metformin plus dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, for patients with type 2 diabetes mellitus (T2DM).Materials and MethodsIn a multicentre study, with a randomized, double‐blind, placebo‐controlled design, 249 Korean patients with T2DM suboptimally managed on metformin and dapagliflozin
-
Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta‐regression analysis of 120 randomized controlled trials Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-01 Kris G. Vargas, Tobias Rütten, Benedikt Siemes, Maximilian Brockmeyer, Claudio Parco, Alexander Hoss, Sabrina Schlesinger, Christian Jung, Michael Roden, Malte Kelm, Georg Wolff, Oliver Kuss
AimsTo assess the potential for precision medicine in type 2 diabetes by quantifying the variability of body weight as response to pharmacological treatment and to identify predictors which could explain this variability.MethodsWe used randomized clinical trials (RCTs) comparing glucose‐lowering drugs (including but not limited to sodium‐glucose cotransporter‐2 inhibitors, glucagon‐like peptide‐1 receptor
-
Blood glucose control using a mobile health application in Singapore, Philippines and Hong Kong: a retrospective real‐world data analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Yi Hui Tan, Wen Lee Tan, Valerie Eichinger, Bernhard Ruch, Ester Yeoh
CONFLICT OF INTEREST STATEMENT WLT is an employee of Roche Diabetes Care Asia Pacific Pte Ltd. VE and BR are employees of mySugr GmbH. YHT and EY have no conflicts of interest to declare.
-
Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Caroline Swift, Monica Frazer, Noelle N. Gronroos, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J. Dunn, Josh Noone, Mico Guevarra
AimTo describe the change in glycated haemoglobin (HbA1c) among patients with type 2 diabetes following treatment with a 7 or 14 mg maintenance dose of oral semaglutide.Materials and MethodsThis retrospective, claims‐based study included adult patients with type 2 diabetes with a pre‐index HbA1c of ≥7%, initiating treatment with oral semaglutide between 1 November 2019 and 30 June 2020; the patients
-
Pharmacological treatment of obesity in adults in Norway 2004–2022 Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Paz Lopez‐Doriga Ruiz, Øystein Karlstad, Kjersti Nøkleby, Kristina Slåtsve, Hanne L. Gulseth, Haakon E. Meyer, Kari Anne Sveen, Elisabeth Qvigstad, Kari Furu
AimsTo describe trends in the use of anti‐obesity drugs in Norway during the period 2004–2022.Materials and MethodsWe assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18–79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18–29 years and 10‐year age
-
Insulin resistance before type 2 diabetes onset is associated with increased risk of albuminuria after diabetes onset: A prospective cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Meeah R. Willig, Emma J. Stinson, Helen C. Looker, Paolo Piaggi, Cassie M. Mitchell, Robert L. Hanson, Robert G. Nelson, Jonathan Krakoff, Douglas C. Chang
AimReduced renal insulin signalling is implicated in the pathogenesis of albuminuria. We sought to investigate whether insulin action and secretion, measured before diabetes onset, are associated with the development of albuminuria after diabetes onset.Materials and MethodsBaseline body composition, insulin sensitivity by hyperinsulinaemic‐euglycaemic clamp at submaximal and maximal insulin stimulation
-
Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China‐PAR project Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Yang Zhao, Minghui Han, Ranran Qie, Yanyan Zhang, Yuying Wu, Xueru Fu, Dongdong Zhang, Lei Kuang, Pei Qin, Fulan Hu, Jianxin Li, Xiangfeng Lu, Dongsheng Hu, Ming Zhang
AimsTo identify the trajectories of body mass index (BMI) and waist circumference (WC), and assess the associations of BMI trajectory, WC trajectory, or the two combined, with type 2 diabetes mellitus (T2DM) risk in Chinese adults.Materials and MethodsThis study was based on a prospective project—the Prediction for Atherosclerotic Cardiovascular Disease Risk in China (China‐PAR). A total of 54 434
-
The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD‐REIN cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Fabrice Bonnet, Beverley Balkau, Oriane Lambert, Yakhara Diawara, Christian Combe, Luc Frimat, Maurice Laville, Sophie Liabeuf, Ziad A. Massy, Marie Metzger, Bénédicte Stengel, Natalia Alencar de Pinho, Denis Fouque
AimThe risk of cardiorenal events remains high among patients with diabetes and chronic kidney disease (CKD), despite the prescription of recommended treatments. We aimed to determine whether the attainment of a combination of nephroprotection targets at baseline (glycated haemoglobin <7.0%, urinary albumin‐creatinine ratio <300 mg/g, blood pressure <130/80 mmHg, renin‐angiotensin system inhibition)
-
Bridging dose of U‐100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice‐daily glargine users Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Arthi Thirumalai, Jing H. Chao, Thanmai Kaleru, Xiaofu Dong, Patali Mandava, Dori Khakpour, Irl B. Hirsch
AimsTo study the effects of a bridging dose of U‐100 glargine (U‐100G) with the first dose of degludec in type 1 diabetes (T1D) patients transitioning from glargine to degludec, by comparing the glucose metrics 48 h before and after the transition.Materials and MethodsPatients with T1D on a stable U‐100G regimen and with glycated haemoglobin concentration <75 mmol/mol were randomized (double‐blind)
-
Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-28 Hiroaki Iijima, Maki Gouda, Hideaki Hida, Kazumi Mori‐Anai, Akiko Takahashi, Ryoichi Minai, Hideki Ninomiya, Yoshiyuki Saito, Atsushi Miyawaki, Jun Wada
AimTo evaluate whether sodium‐glucose cotransporter 2 inhibitor (SGLT2i) therapy is associated with a reduction of renal events compared with other glucose‐lowering drugs (oGLDs) among Japanese people with type 2 diabetes (T2D) and grade 3 (G3) chronic kidney disease (CKD) in a real‐world clinical practice setting.Materials and MethodsPeople with T2D who were newly prescribed an SGLT2i or an oGLD from